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In the May 2010 issue of the Journal of the Chinese
Medical Association, Chuang et al1 reported their inves-
tigation of whether diabetic patients without prior
heart disease have a similar risk of cardiovascular (CV)
mortality as heart disease patients without diabetes
mellitus (DM), and whether the presence of hyperten-
sion or metabolic syndrome enhances CV mortality
risk in the DM patients identified from a community-
based, homogeneous population of Chinese. Their
study followed 11,058 Chinese aged ≥ 30 years on
Kinmen island for a median of 15 years, and the results
revealed that DM subjects without heart disease had 
a similar risk of CV mortality as heart disease subjects
without DM in this population. Among the 827 DM
subjects without heart disease identified at baseline sur-
veys, the presence of hypertension but not metabolic
syndrome substantially increased CV mortality risk.
The study provides further evidence in a Chinese
population that is similar to previous reports in other
populations. Haffner et al2 examined the 7-year inci-
dence of fatal and nonfatal myocardial infarction (MI)
of 1,373 nondiabetic and 1,059 diabetic subjects to
determine whether patients with DM who have not
had MI should be treated as aggressively for CV risk
factors as patients who have had MIs. The data sug-
gest that diabetic patients without previous MI have
as high a risk of MI as nondiabetic patients with pre-
vious MI. The Prospective Cardiovascular Münster
Study3 showed that rates of MI over a 4-year follow-
up period in a group of middle-aged men were in-
creased by nearly 3 times in people with DM compared
to people without DM. When DM and hypertension
occurred together, the incidence of MI was 8-fold
greater than in subjects without any risk factors. If dys-
lipidemia was also present, a further 2-fold increase in
risk was observed. These data confirm both the inde-
pendent risk associated with DM and the synergistic
interaction that DM has with other common risk 
factors for coronary heart disease.
So, there are 2 major questions regarding DM and
CV risk. First, whether or not routine screening for 
coronary artery disease identifies patients with type 
2 DM as being at high cardiac risk, and whether it affects
their cardiac outcomes. Second, whether or not im-
proved glycemic control in DM patients reduces their
CV risk and mortality. Type 2 DM is also widely rec-
ognized as a CVD risk equivalent, and CVD is often
asymptomatic in these patients until the onset of MI
or sudden cardiac death. The current standard of care
for type 2 DM emphasizes reduction of CV risk fac-
tors.4 Although endorsed by some professional organ-
izations, screening of patients with type 2 DM and no
symptoms of coronary artery disease remains highly
controversial in the absence of prospective outcome
studies supporting its utility. The Detection of Ischemia
in Asymptomatic Diabetics (DIAD) study is a random-
ized controlled trial in which participants were ran-
domly assigned either to be systematically screened
with stress myocardial perfusion imaging or not be
screened.5 The aim of DIAD was to test the hypothe-
sis that systematic screening would identify higher-
risk individuals and beneficially affect their risk of MI
or cardiac death. Overall, cardiac event rates in this
population were much lower than anticipated. Within
this population of patients with asymptomatic type 2
DM, the use of myocardial perfusion imaging screen-
ing had no discernable effect on subsequent cardiac
events. The results also showed that significant myo-
cardial perfusion imaging abnormalities on screening
were associated with a greater incidence of cardiac
events, although the positive predictive value of such
abnormalities was low and events also occurred in par-
ticipants with normal screening tests. In this contem-
porary study population of patients with DM, the
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cardiac event rates were low and were not significantly
reduced by myocardial perfusion imaging screening
for myocardial ischemia over 4.8 years.
Epidemiologic evidence strongly indicates that DM
is a major risk factor for CV disease (CVD). Clinical
trials have shown that intensive glucose control reduces
the risk of microvascular complications among patients
with type 2 DM, but its effect on CVD, including
coronary heart disease, stroke and peripheral arterial
disease, is uncertain. However, during 2008, 3 large
randomized controlled trials reported conflicting re-
sults.6–8 Although ADVANCE (Action in Diabetes and
Vascular Disease: Preterax and Diamicron Modified
Release Controlled Evaluation) and VADT (Veterans
Affairs Diabetes Trial) found no effect of intensive glu-
cose control on major CV events,7,8 ACCORD (Action
to Control Cardiovascular Disease in Diabetes) iden-
tified an increased risk of death from CV causes and
total mortality associated with intensive glucose con-
trol.6 The ACCORD trial was stopped prematurely
because of an excess overall mortality among the DM
patients who were randomized to the intensive gly-
cemic control treatment arm.6 These patients attained
an A1C concentration of 6.0% when compared to the
standard glycemic control arm in which the target
was to attain a concentration of A1C between 7.0%
and 7.9%. Even though there was a non-statistically
significant 10% reduction in the primary composite
outcome of nonfatal MI, stroke or CV death, the trial
was stopped because of the increased overall mortal-
ity. The specific cause of the increased mortality with
intensive glycemic control is not presently known but
was apparently not due to any specific therapy (includ-
ing rosiglitazone) or to hypoglycemia-related events.
The results of the ACCORD, ADVANCE and VADT
trials do not suggest that intensive glycemic control is
associated with a reduction in CV events, at least with
the treatments used in these studies and the length 
of the follow-up periods.
So, is there no benefit of intensive blood glucose
control on CVD in DM patients? Ray et al9 under-
took a meta-analysis of randomized controlled trials to
determine whether or not intensive glycemic control
is beneficial. Their data suggested that intensive com-
pared with standard glycemic control significantly re-
duces CV events without an increased risk of death.
Kelly et al,10 who reviewed 5 large trials, found that
compared with conventional control, intensive glu-
cose control reduced the risk of CVD but not of 
CV death or all-cause mortality, and increased the risk
of severe hypoglycemia. As the American Diabetes
Association has noted, it is likely that the increase in
mortality in ACCORD was related to the overall
treatment strategies for intensifying glycemic control
in the study population, not the achieved A1C per se.4
The ADVANCE study achieved a median A1C in 
its intensive arm similar to that in the ACCORD
study, with no increased mortality hazard. Thus, the
ACCORD mortality findings do not imply that pa-
tients with type 2 DM who can easily achieve or main-
tain low A1C levels with lifestyle modifications with
or without pharmacotherapy are at risk and need to
increase their A1C. We can find the nadir part of the
observational glycemia–CVD risk curves in these 3 tri-
als with the A1C levels in the median of the intensive
arms (6.4–6.9%). Importantly, their results should
not be extrapolated to imply that there would be no
CV benefit of glycemic control from very poor (e.g.
A1C > 9%) to good (e.g. A1C < 7%).
In my view, DM is associated with a marked in-
crease in the risk of CVD, and multiple modifiable risk
factors for CVD are present in diabetic patients, includ-
ing hyperglycemia, hypertension and dyslipidemia. 
A multifactorial intervention, with therapies directed
toward modifying lifestyle, reducing total cholesterol,
lowering blood pressure, and improving glycemic con-
trol, may have a dramatic benefit in diabetic patients,
and be better than an approach that is specifically tar-
geted to only 1 CV risk factor.
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